Almitas Capital’s VistaGen Therapeutics VTGN Stock Holding History

Almitas Capital’s Portfolio VTGN Stock Details VTGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-261,399	Closed	-$928K	–	117
2025 Q3	$928K	Hold	261,399	–	–	0.21%	44
2025 Q2	$523K	Buy	261,399 +6,744	+3%	+$15.3K	0.13%	58
2025 Q1	$637K	Hold	254,655	–	–	0.21%	56
2024 Q4	$751K	Buy	+254,655	New	+$717K	0.16%	62

Other funds holding VTGN

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Luminus Management Houston, Texas $166M AUM 75.95% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Almitas Capital's VTGN Position: Q4 2025 in Review

Almitas Capital sold out of VistaGen Therapeutics (VTGN) in Q4 2025, closing a stake of 261,399 shares — an estimated $928K sold.

Almitas Capital first reported a position in VTGN in Q4 2024 and held it in 4 quarters. The position peaked at $928K in Q3 2025. 55 funds tracked by Wall St. Rank hold VTGN as of Q4 2025.

Almitas Capital reported no remaining VistaGen Therapeutics position as of Q4 2025 after selling out during the quarter.
Almitas Capital sold 261,399 VistaGen Therapeutics shares in Q4 2025, an estimated $928K.
Almitas Capital first reported a position in VistaGen Therapeutics in Q4 2024 and held it in 4 quarters.
Almitas Capital's VistaGen Therapeutics position peaked at $928K in Q3 2025.
55 funds tracked by Wall St. Rank held VistaGen Therapeutics as of Q4 2025.

Based on Almitas Capital's 13F filing for Q4 2025, filed 17 Feb 2026.